Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

Korman, 2006, Checkpoint blockade in cancer immunotherapy, Adv Immunol, 90, 297, 10.1016/S0065-2776(06)90008-X Carter, 2002, PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2, Eur J Immunol, 32, 634, 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9 Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, 192, 1027, 10.1084/jem.192.7.1027 Latchman, 2001, PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat Rev Immunol, 2, 261, 10.1038/85330 McDermott, 2013, PD-1 as a potential target in cancer therapy, Cancer Med, 2, 662, 10.1002/cam4.106 Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, 27, 450, 10.1016/j.ccell.2015.03.001 Homet Moreno, 2015, Anti-PD-1 therapy in melanoma, Semin Oncol, 42, 466, 10.1053/j.seminoncol.2015.02.008 2016 2016 Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, 369, 134, 10.1056/NEJMoa1305133 Ribas, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, 16, 908, 10.1016/S1470-2045(15)00083-2 Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, 372, 2521, 10.1056/NEJMoa1503093 Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 16, 375, 10.1016/S1470-2045(15)70076-8 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030 Cormier, 2011, Assessment of patient-reported outcomes in patients with melanoma, Surg Oncol Clin N Am, 20, 201, 10.1016/j.soc.2010.09.002 Osoba, 1998, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 16, 139, 10.1200/JCO.1998.16.1.139 Kiebert, 2003, Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine, Cancer Invest, 21, 821, 10.1081/CNV-120025084 Schadendorf, 2014, Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study, Ann Oncol, 25, 700, 10.1093/annonc/mdt580 Schadendorf, 2015, Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma, Eur J Cancer, 51, 833, 10.1016/j.ejca.2015.03.004 Grob, 2015, Lancet Oncol, 16, 1389, 10.1016/S1470-2045(15)00087-X Quinten, 2014, A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites, Cancer, 120, 302, 10.1002/cncr.28382 Montazeri, 2009, Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008, Health Qual Life Outcomes, 7, 102, 10.1186/1477-7525-7-102